Exome Recapture and Sequencing of Prospectively Characterized Clinical Specimens From Cancer Patients

The study cohort comprises samples from patients whose tumors have been prospectively characterized as part of their care at Memorial Sloan Kettering Cancer Center. This includes a variety of distinct tumor type and molecular subtypes. ]]>
DNA samples from tumor tissue were from patients at Memorial Sloan Kettering Cancer Center. Tumor and normal sample libraries prepared for targeted MSK-IMPACT sequencing were recaptured for exome sequencing. Study participants were not selected on the basis of tumor type, molecular features of their tumor, or treatments.]]>

本研究队列的样本来自纪念斯隆凯特琳癌症中心（Memorial Sloan Kettering Cancer Center）的患者，这些患者的肿瘤作为其临床诊疗的一部分已被前瞻性表征。该队列涵盖多种不同的肿瘤类型与分子亚型。

肿瘤组织的DNA样本均取自纪念斯隆凯特琳癌症中心的患者。为靶向MSK-IMPACT测序制备的肿瘤与正常样本文库，经重捕获后用于外显子组测序。本研究的入组受试者未依据肿瘤类型、肿瘤分子特征或治疗方案进行筛选。